de la Fuente, A.; Santisteban, M.; Lupón, J.; AramendÃa, J.M.; DÃaz, A.; Santaballa, A.; Hernándiz, A.; Sepúlveda, P.; Cediel, G.; López, B.;
et al. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers 2022, 14, 2941.
https://doi.org/10.3390/cancers14122941
AMA Style
de la Fuente A, Santisteban M, Lupón J, AramendÃa JM, DÃaz A, Santaballa A, Hernándiz A, Sepúlveda P, Cediel G, López B,
et al. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers. 2022; 14(12):2941.
https://doi.org/10.3390/cancers14122941
Chicago/Turabian Style
de la Fuente, Ana, Marta Santisteban, Josep Lupón, José Manuel AramendÃa, Agnes DÃaz, Ana Santaballa, Amparo Hernándiz, Pilar Sepúlveda, Germán Cediel, Begoña López,
and et al. 2022. "A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy" Cancers 14, no. 12: 2941.
https://doi.org/10.3390/cancers14122941
APA Style
de la Fuente, A., Santisteban, M., Lupón, J., AramendÃa, J. M., DÃaz, A., Santaballa, A., Hernándiz, A., Sepúlveda, P., Cediel, G., López, B., Picazo, J. M. L., Mazo, M. M., Rábago, G., Gavira, J. J., GarcÃa-Bolao, I., DÃez, J., González, A., Bayés-GenÃs, A., & Ravassa, S.
(2022). A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers, 14(12), 2941.
https://doi.org/10.3390/cancers14122941